Friday, 16 October 2026European Markets

GRIEG SEAFOOD Stock Went Up By Over 10% So Far Today

Loading stream...

(VIANEWS) - Shares of GRIEG SEAFOOD (Oslo Børs Benchmark Index_GI: GSF.OL) jumped by a staggering 10.52% to kr90.90 at 14:37 EST on Thursday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is rising 0.82% to kr1,231.28, following the last session's downward trend. This seems, up to now, a somewhat positive trend exchanging session today.

GRIEG SEAFOOD's last close was kr82.25, 47.34% under its 52-week high of kr156.20.

About GRIEG SEAFOOD

Grieg Seafood ASA, through its subsidiaries, operates as a fish farming company in Norway, rest of Europe, the United States, Canada, Asia, and internationally. It engages in the production and sale of Atlantic salmon. The company was founded in 1884 and is headquartered in Bergen, Norway. Grieg Seafood ASA operates as a subsidiary of Grieg Aqua AS.

Earnings Per Share

As for profitability, GRIEG SEAFOOD has a trailing twelve months EPS of kr7.29.

PE Ratio

GRIEG SEAFOOD has a trailing twelve months price to earnings ratio of 12.47. Meaning, the purchaser of the share is investing kr12.47 for every norwegian krone of annual earnings.

More news about GRIEG SEAFOOD (GSF.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com